Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Clinical trials showed a high response rate, with almost 85% of participants experiencing tumor shrinkage with this targeted drug.
In a clinical trial, 46% of responding participants experienced a complete response lasting at least 12 months.
PARP inhibitor delays disease progression when used after successful chemotherapy.
60% of women treated with the antibody-drug conjugate experienced complete or partial tumor shrinkage.
Novel antibody-drug conjugate shrank tumors in more than 40% of people previously treated with immunotherapy.
The drug was previously approved for castration-resistant prostate cancer.
New site-agnostic therapies highlight the importance of genetic testing.
Even some of the newest, most expensive brand-name medicines have been plagued by quality and safety concerns during production.
Clinical trials showed that 84% of patients saw tumor shrinkage with this therapy.
Acting Commissioner Ned Sharpless will return to lead the National Cancer Institute.
The indication is for people with advanced ovarian, fallopian tube, or primary peritoneal cancer treated with prior chemotherapy regimens.
The approval is based on data from CASSIOPEIA, an open-label, randomized, active-controlled phase 3 study.
Recent legislation may help narrow the gap between FDA approval of cancer medications for adults and children.
Keytruda plus Lenvima is first approval under Project Orbis collaboration.
AACR report highlights progress in preventing and treating cancer—including 27 new drug approvals last year—but disparities persist.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.